News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Oncoceutics Begins Fifth Clinical Trial for ONC201

Al's Comment:

 This is a new clinical trial for recurrent GBMs.  This is a new approach, with a new target. It is an oral medication. See oncoceutics.com/therapeutic-approach/

for details on the mechanism.   I will be watching this closely - as the Musella Foundation gave them a research grant a few years ago to help do the preclinical work on this new drug - which came out pretty good!

 

 


Posted on: 01/21/2016

Oncoceutics Begins Fifth Clinical Trial for ONC201

 

Philadelphia (January 21, 2016) – Oncoceutics, Inc. announced that patient enrollment has commenced for a clinical trial at the Massachusetts General Hospital (MGH) of the company’s lead compound, ONC201, in glioblastoma multiforme (GBM). The trial, identified as NCT02525692 on www.clinicaltrials.gov, is entitled “Oral ONC201 in Adult Recurrent Glioblastoma”.

 

The Phase II trial will investigate the use of single agent ONC201 in adult patients with glioblastoma who have relapsed or are refractory to other therapies and have not been treated with bevacizumab.  Isabel Arrillaga-Romany, MD, PhD, an oncologist in the Department of Neurology at MGH, is the Principal Investigator for the trial, under the guidance of Tracy Batchelor, MD, MPH, Director, Division of Neuro-Oncology. The study will also enroll patients at the Dana-Farber Cancer Institute.

 

Since completing the first-in-man phase I dose escalation study at Rutgers Cancer Institute of New Jersey (CINJ) in July 2015 that established the safety and recommended Phase II dose (RP2D), Oncoceutics has enrolled patients in five additional clinical trials at four of the leading cancer centers in the United States:

 

Initiation Date

Indication

Location

July 2015

Solid Tumors (expansion phase)

Rutgers Cancer Institute of New Jersey

Nov 2015

Solid Tumors and Multiple Myeloma

Fox Chase Cancer Center

Dec 2015

Non-Hodgkin’s Lymphoma

MD Anderson Cancer Center

Dec 2015

Acute Leukemias

MD Anderson Cancer Center

Jan 2016

Glioblastoma Multiforme

Massachusetts General Hospital

 

These five trials will allow the company to enroll over 200 patients. 

 

“We are extremely pleased to have opened five clinical trials at four of the leading cancer centers in the United States just months after completing our phase I trial,” said Lee Schalop, MD, Chief Business Officer and co-founder of Oncoceutics.  “We are indebted to our scientific collaborators and Principal Investigators at these institutions for moving ONC201 so quickly into their clinical programs.”

 

Wolfgang Oster, MD PhD, CEO, Chairman and co-founder of Oncoceutics, added, “The efficacy and therapeutic index of ONC201, its activity on cancer stem cells and cancer cells that exhibit complex resistance mechanisms, along with a convenient oral intake regimen position this drug as a much needed and promising alternative therapy.  Given the positive results from the completed phase I clinical trial and multiple pre-clinical models of challenging tumor types, we are optimistic that ONC201 will offer an opportunity for patients to experience real benefit without toxicity.”

 

About Oncoceutics

Oncoceutics, Inc. is a clinical-stage drug discovery and development company targeting potent suppressor pathways in human cancer. The first lead compound that entered clinical development from this program is ONC201, a small molecule with an active angular structure and a first-in-class mechanism of action that causes significant anti-tumor activity in a variety of human cancers. The company recently completed a successful Phase I study in solid tumors and has begun Phase II clinical programs in both solid and hematological malignancies. Oncoceutics has been awarded several competitive grants for its development programs with ONC201 and its other candidates in this new class of compounds. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center.  The company has established a robust Intellectual property position, including several issued patents.

 

Visit Oncoceutics or contact Rohinton Tarapore for more information.

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740